-
Non Regulatory September 25, 2023 EnglishResult of incentive program LTI2023 in Initiator Pharma
-
Non Regulatory September 19, 2023 EnglishInitiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction
-
Regulatory August 25, 2023 EnglishINITIATOR PHARMA: Q2 2023 REPORT
-
Regulatory August 25, 2023 EnglishINITIATOR PHARMA: Q2 2023 REPORT
-
Regulatory May 5, 2023 EnglishINITIATOR PHARMA: Q1 2023 REPORT
-
Regulatory May 2, 2023 EnglishAnnual report and Remuneration report 2022 for Initiator Pharma A/S
Share
Initiator Pharma Numbers
-
Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
-
Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
-
Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.
CEO letter
The positive momentum for Initiator Pharma has continued during the second quarter, with several key milestones reached, including the announcement of statistically significant efficacy data for IP2018 and completion of patient recruitment in the Phase IIb trial with IP2015, now referred to as its INN name, pudafensine. After the end of the period, we also announced positive results from the Phase I pharmacokinetic trial with new oral formulations of pudafensine.
